Provided by Tiger Trade Technology Pte. Ltd.

iShares Biotechnology ETF

202.40
+0.40000.20%
Pre-market: 203.200.8000+0.40%08:11 EDT
Volume:1.10M
Turnover:222.83M
Market Cap:10.31B
PE:32.07
High:204.16
Open:202.49
Low:200.98
Close:202.00
52wk High:217.12
52wk Low:138.79
Shares:50.95M
Float Shares:50.95M
Volume Ratio:0.64
T/O Rate:2.16%
Dividend:0.34
Dividend Rate:0.17%
EPS(TTM):6.31
EPS(LYR):35.34
ROE:24.54%
ROA:0.10%
PB:1.27
PE(LYR):5.73

Loading ...

Amgen Pulls Dow Industrials Lower; Oil Jumps on Houthi Strikes in Saudi Arabia

Dow Jones
·
Sep 09

Top Midday Stories: GE Aerospace to Acquire Consolidated Precision Products; Qualcomm Issues Share Warrant to Amazon

MT Newswires Live
·
Sep 08

European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading

MT Newswires Live
·
Sep 08

NASDAQ Top and Bottom Performing Stocks at About 11:01 A.m. EDT on 2026-09-08

Reuters
·
Sep 08

Amgen Says Phase 3 Study Meets Primary Endpoint in Small Cell Lung Cancer

MT Newswires Live
·
Sep 08

Amgen Inc Stock (AMGN) Moved Down by 8.33% on Sep 8: A Full Analysis

TradingKey
·
Sep 08

U.S. Stocks on the MOVE-Sigma Lithium, Shake Shack, Novartis

Reuters
·
Sep 08

Dow Drops 438 Points on Losses for Amgen, Salesforce Shares

Dow Jones
·
Sep 08

Amgen Down Nearly 7%, on Pace for Largest Percent Decrease Since March 2020

Dow Jones
·
Sep 08

Argenx Price Target Maintained with a $1150.00/Share by Wedbush

Dow Jones
·
Sep 08

Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday Amid Rising Oil Prices

MT Newswires Live
·
Sep 08

Amgen-AstraZeneca Cancer Drug Combo Hits Main Survival Goal in Late-Stage Trial

Reuters
·
Sep 08

AstraZeneca announces results from Phase III trial of IMFINZI, tarlatamab

TIPRANKS
·
Sep 08

Sector Update: Healthcare

MT Newswires Live
·
Sep 08

Amgen - Phase 3 Dellphi-305 Study Delivers Significant Overall Survival Benefit Versus Durvalumab Alone

THOMSON REUTERS
·
Sep 08

Imdelltra® in Combination with Imfinzi® Demonstrated Landmark Improvement in Overall Survival in First-Line Extensive Stage Small Cell Lung Cancer

THOMSON REUTERS
·
Sep 08

Amgen - Study Meets Secondary Endpoints for Progression-Free Survival and Objective Response Rate

THOMSON REUTERS
·
Sep 08

Amgen - no New or Unexpected Safety Signals Identified in Dellphi-305 Study

THOMSON REUTERS
·
Sep 08

Analysts Offer Insights on Healthcare Companies: Amgen (AMGN), Guardant Health (GH) and Neurocrine (NBIX)

TIPRANKS
·
Sep 08

Structure Therapeutics reports ACCG-2671, aleniglipron trial results

TIPRANKS
·
Sep 08